Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8066975 | GALDERMA LABS | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun, 2019
(4 years ago) | |
US8066976 | GALDERMA LABS | Foaming compositions for hair care |
Jun, 2019
(4 years ago) | |
US7316810 | GALDERMA LABS | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun, 2019
(4 years ago) | |
US7700081 | GALDERMA LABS | Foaming compositions for hair care |
Jan, 2022
(2 years ago) |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 05 February, 2004
Treatment: Topical treatment of scalp psoriasis
Dosage: SHAMPOO;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8909305 | GALDERMA LABS | Method and system for activating an application on a mobile device |
Dec, 2022
(1 year, 4 months ago) | |
US8785420 | GALDERMA LABS | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Dec, 2022
(1 year, 4 months ago) | |
US9814690 | GALDERMA LABS | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(1 year, 4 months ago) | |
US8936800 | GALDERMA LABS | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(1 year, 4 months ago) | |
US8809305 | GALDERMA LABS | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
Dec, 2022
(1 year, 4 months ago) | |
US8445543 | GALDERMA LABS | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Dec, 2022
(1 year, 4 months ago) | |
US8703820 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
US8729127 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
US9381179 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
US9387187 | GALDERMA LABS | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 15, 2018 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 15 July, 2015
Treatment: Treatment of acne
Dosage: GEL;TOPICAL